Cargando…

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms

BACKGROUND: Vasomotor symptoms (VMS), such as hot flashes and night sweats, are the most bothersome symptoms of menopause and affect an estimated 75% of women aged over 50 years. OBJECTIVES: To discuss the burden, pathophysiology, and management of menopause-associated VMS and to evaluate pharmacolo...

Descripción completa

Detalles Bibliográficos
Autor principal: Umland, Elena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2008
Materias:
Cea
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437968/
http://dx.doi.org/10.18553/jmcp.2008.14.S3-A.14
_version_ 1785092662656761856
author Umland, Elena M.
author_facet Umland, Elena M.
author_sort Umland, Elena M.
collection PubMed
description BACKGROUND: Vasomotor symptoms (VMS), such as hot flashes and night sweats, are the most bothersome symptoms of menopause and affect an estimated 75% of women aged over 50 years. OBJECTIVES: To discuss the burden, pathophysiology, and management of menopause-associated VMS and to evaluate pharmacologic options available for the treatment of VMS, including herbal remedies, hormone replacement therapy (HRT), and nonhormonal therapies. SUMMARY: Lifestyle changes, including regulation of core body temperature, relaxation techniques, regular physical activity, weight loss, and smoking cessation may help reduce the risk of VMS and should be implemented by all women with menopause-associated VMS. The role of herbal remedies in the treatment of VMS remains unclear, as clinical trial efficacy data are inconsistent and inconclusive. Nevertheless, soy isoflavones, red clover isoflavones, black cohosh, and vitamin E are commonly used to treat VMS and may be considered in women with mild symptoms that are not controlled by lifestyle changes alone. These herbal remedies appear to be safe when used for short durations (d 6 months). HRT, consisting of estrogen (in women without a uterus) or estrogen plus progestin (in women with a uterus) is the most widely studied and most effective treatment option for relief of menopause-associated VMS and is considered the standard of care for women with moderate-to-severe VMS. HRT should be used at the lowest effective dose and for the shortest duration possible (preferably d 5 years) in women in whom the potential benefits outweigh the potential risks. Nonhormonal therapies, such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, and clonidine, may be appropriate alternatives in women who cannot or will not use HRT for VMS relief, such as those with a history of or at risk for breast cancer. CONCLUSIONS: The physical and financial burden imposed by menopause associated VMS is immense. Optimum management of VMS includes lifestyle changes in all women and HRT in women with moderate to severe symptoms. Less effective herbal remedies or nonhormonal therapies may be appropriate in certain women, such as those with mild symptoms or those who cannot or will not take HRT.
format Online
Article
Text
id pubmed-10437968
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104379682023-08-21 Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms Umland, Elena M. J Manag Care Pharm Cea BACKGROUND: Vasomotor symptoms (VMS), such as hot flashes and night sweats, are the most bothersome symptoms of menopause and affect an estimated 75% of women aged over 50 years. OBJECTIVES: To discuss the burden, pathophysiology, and management of menopause-associated VMS and to evaluate pharmacologic options available for the treatment of VMS, including herbal remedies, hormone replacement therapy (HRT), and nonhormonal therapies. SUMMARY: Lifestyle changes, including regulation of core body temperature, relaxation techniques, regular physical activity, weight loss, and smoking cessation may help reduce the risk of VMS and should be implemented by all women with menopause-associated VMS. The role of herbal remedies in the treatment of VMS remains unclear, as clinical trial efficacy data are inconsistent and inconclusive. Nevertheless, soy isoflavones, red clover isoflavones, black cohosh, and vitamin E are commonly used to treat VMS and may be considered in women with mild symptoms that are not controlled by lifestyle changes alone. These herbal remedies appear to be safe when used for short durations (d 6 months). HRT, consisting of estrogen (in women without a uterus) or estrogen plus progestin (in women with a uterus) is the most widely studied and most effective treatment option for relief of menopause-associated VMS and is considered the standard of care for women with moderate-to-severe VMS. HRT should be used at the lowest effective dose and for the shortest duration possible (preferably d 5 years) in women in whom the potential benefits outweigh the potential risks. Nonhormonal therapies, such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, and clonidine, may be appropriate alternatives in women who cannot or will not use HRT for VMS relief, such as those with a history of or at risk for breast cancer. CONCLUSIONS: The physical and financial burden imposed by menopause associated VMS is immense. Optimum management of VMS includes lifestyle changes in all women and HRT in women with moderate to severe symptoms. Less effective herbal remedies or nonhormonal therapies may be appropriate in certain women, such as those with mild symptoms or those who cannot or will not take HRT. Academy of Managed Care Pharmacy 2008-04 /pmc/articles/PMC10437968/ http://dx.doi.org/10.18553/jmcp.2008.14.S3-A.14 Text en Copyright © 2008, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Cea
Umland, Elena M.
Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
title Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
title_full Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
title_fullStr Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
title_full_unstemmed Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
title_short Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
title_sort treatment strategies for reducing the burden of menopause-associated vasomotor symptoms
topic Cea
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437968/
http://dx.doi.org/10.18553/jmcp.2008.14.S3-A.14
work_keys_str_mv AT umlandelenam treatmentstrategiesforreducingtheburdenofmenopauseassociatedvasomotorsymptoms